SMARCA4 is frequently mutated in multiple cancer types, including non-small cell lung carcinoma (NSCLC) (10–35%), Burkitt’s lymphoma (15%) and childhood medulloblastoma (5–10%), and occasionally mutated in pancreatic adenocarcinoma, ovarian clear cell carcinoma and melanoma [19, 32]. This evidence concerns the gene SMARCA4 and Burkitt lymphoma.